A Phase 2 interventional study of UI030 in Coronavirus Infection, sponsored by Korea United Pharm. Inc.. Status unknown. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-09-24.
Sponsored by Korea United Pharm. Inc. · Phase 2, Interventional, and Treatment
This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients
Patients with moderate and severe COVID-19 were randomly assigned (1:1) to receive either UI030 (Budesonide/Arformoterol dry powder inhaler, 2 inhalations b.i.d) or placebo for 2 weeks.
929 studies on the registry are indexed under Coronavirus Infections; 50 are open to participants now.
This study's planned enrollment of 140 is above the median of 107 across 541 interventional studies indexed under Coronavirus Infections.
Browse Coronavirus Infections studies →Korea United Pharm. Inc. is the lead sponsor of 20 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
Drug: UI030
UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
Drug: UI030
Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
Time to Clinical Improvement on World Health Organization (WHO) Ordinal Scale
The median time to reach the clinical improvement on the WHO Ordinal 9 Scale for Clinical Improvement \[0-8\]
Time frame: 28 days
World Health Organization (WHO) Ordinal Scale for Clinical Improvement
Improvement rate of patients with WHO Clinical Ordinal 9 Scale \[0-8\]
Time frame: 28 days
World Health Organization (WHO) Ordinal Scale change
Change from baseline in WHO Ordinal 9 Scale \[0-8\]
Time frame: 28 days
Clinical cure rate
Percentage of patients with clinical cure and improvement
Time frame: 28 days
No study locations are listed for this record.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea United Pharm. Inc.